UNSPSC 51162008: Aminophylline/guaifenesin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162008 Aminophylline/guaifenesin is a Commodity code, but the recent state and local procurement activity tagged under it spans pharmaceutical procurement far more broadly than the code's nominal scope — encompassing naloxone procurement, on-site pharmacy services, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. State and local issuing bodies soliciting under or near this code include county health departments and government family health centers (Seminole County, Florida; Hall County, Georgia), state health and human services commissions (Texas), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participants). The work being solicited ranges from tactical purchases of emergency-response medications (naloxone and drug deactivation systems) and on-site employee pharmacy services to strategic programs redesigning prescription supply chains through direct-to-manufacturer relationships and bulk generic pharmaceutical contracting across participating jurisdictions.

Geographic activity centers on Florida, Georgia, Texas, and the Upper Midwest (Minnesota and Oregon), though MMCAP's multi-state reach extends the Tennessee code's practical footprint. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (posted June 30, 2026, due July 26, 2026); Hall County's RFQ/P #47-010 for on-site pharmacy services at its Family Health Center Clinic in Gainesville (posted May 4, 2026, due June 4, 2026, covering approximately 3,005 eligible individuals with technical qualifications weighted at 80 percent of the evaluation score); Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription program vendors (posted April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026, with contracts effective July 1, 2026). The MMCAP procurement requires vendors to distribute through three authorized wholesalers and absorb a 3 percent administrative fee on all contract purchases.